Eli Lilly and Company (NYSE:LLY) is SeaCrest Wealth Management LLC’s 7th Largest Position

SeaCrest Wealth Management LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 5.5% in the fourth quarter, Holdings Channel reports. The institutional investor owned 20,302 shares of the company’s stock after purchasing an additional 1,065 shares during the period. Eli Lilly and Company accounts for about 1.5% of SeaCrest Wealth Management LLC’s portfolio, making the stock its 7th largest position. SeaCrest Wealth Management LLC’s holdings in Eli Lilly and Company were worth $12,558,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares in the last quarter. State Street Corp increased its stake in shares of Eli Lilly and Company by 1.9% during the second quarter. State Street Corp now owns 33,878,417 shares of the company’s stock worth $15,888,300,000 after purchasing an additional 642,274 shares in the last quarter. Morgan Stanley increased its stake in shares of Eli Lilly and Company by 0.7% during the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after purchasing an additional 83,915 shares in the last quarter. Northern Trust Corp increased its stake in shares of Eli Lilly and Company by 3.6% during the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after purchasing an additional 355,317 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $3,416,206,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.0 %

NYSE:LLY traded down $0.22 on Friday, hitting $777.96. The stock had a trading volume of 3,209,424 shares, compared to its average volume of 2,972,386. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a market cap of $739.19 billion, a price-to-earnings ratio of 134.13, a PEG ratio of 1.71 and a beta of 0.34. The company has a fifty day moving average price of $730.97 and a two-hundred day moving average price of $637.01. Eli Lilly and Company has a 1-year low of $334.58 and a 1-year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the company posted $2.09 EPS. Equities research analysts expect that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on LLY shares. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $689.52.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 34,538 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the completion of the transaction, the insider now owns 99,719,884 shares of the company’s stock, valued at approximately $63,004,019,910.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 195,055 shares of company stock valued at $125,254,657. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.